Jam

Quest Diagnostics’ Chairman, CEO, and President, Jim Davis, will speak at the Baird 2025 Global Healthcare Conference on September 10, 2025. He will discuss the company’s strategy, performance, and healthcare market trends. A live webcast of the presentation will be available on the Quest Diagnostics investor relations website, with a replay archived for later viewing. Quest Diagnostics aims to improve health outcomes through its extensive diagnostic testing and insights, serving a large segment of the U.S. population.

BlackRock will terminate the iShares iBonds Oct 2025 Term TIPS ETF (IBIB) with a last trading day of October 15, 2025, and a liquidation date around October 20, 2025. iBonds ETFs wind down as they approach their target date, shifting to short-term instruments and cash. BlackRock will continue to offer a range of iBonds ETFs across various asset classes. Investors should review fund objectives and risks in the prospectus before investing, remembering all investing involves risk.

Duke Energy filed an application with FERC to extend the operating license of its Bad Creek Pumped Storage Hydroelectric Station in South Carolina for 50 years. This facility, operating since 1991, is a key energy storage asset on Duke Energy’s grid. The relicensing supports South Carolina’s growth and helps maintain reliable, affordable energy. Recent upgrades increased the plant’s capacity to 1,680 MW of carbon-free energy. A decision from FERC is expected in 2027.

Bioxytran’s (BIXT) is advancing tissue-specific oxygen monitoring with the publication of research by Prof. Mayevsky. The research addresses limitations of current oxygen measurements and aims to revolutionize treatment for conditions like stroke and Alzheimer’s. Bioxytran’s MDX Viewer technology and BXT-25 program will serve as a crucial biomarker in clinical trials, potentially transforming oxygen delivery management. The technology targets a shift from peripheral to tissue-specific oxygenation monitoring.

Georgia Power is adding three new natural gas turbines to Plant Yates, its first such project in a decade, to meet growing energy demand. The first American-made turbine from Mitsubishi Power, weighing 350 tons, has arrived. The expansion will add 1,300 MW of capacity and create 600 construction jobs and 15 permanent roles. The advanced turbines offer quick start-up times and can blend hydrogen for cleaner energy, supporting Georgia’s economic growth.

Columbia Banking System, Inc. (COLB) announced its Board of Directors has approved a quarterly cash dividend of $0.36 per common share. The dividend is payable on September 15, 2025, to shareholders of record as of August 29, 2025. Columbia Bank, a leading regional bank in the Western U.S. with over $50 billion in assets, rebranded from Umpqua Bank on July 1, 2025, and fully operates under the new name as of September 1, 2025.

H World Group (HTHT) announced Board of Directors changes effective August 15, 2025. Justin Martin Leverenz, ex-CIO at Invesco Developing Markets Fund, joins as a director. Yi Zhang (Bonnie Yi Zhang), SINA Corporation’s CFO, becomes an independent director and Audit Committee chairwoman. Lei Cao joins the Compensation Committee. Tong Tong Zhao transitions to Board observer. Jian Shang departs from independent director and committee roles. These changes aim to bolster H World’s strategic growth with diverse financial and emerging market expertise.

Viomi Technology (VIOT) anticipates H1 2025 revenue exceeding RMB 1.4 billion, a 70%+ year-over-year increase. This growth is fueled by strong sales of household water purification equipment, supported by Chinese government subsidies and increasing consumer demand for cleaner water. CEO Xiaoping Chen cites disciplined execution and rising health consciousness as drivers for long-term growth. However, the results are preliminary and unaudited, and reliance on subsidies presents a potential risk.

Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has successfully treated the third patient in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (R/R AML), completing the first adult dose cohort. The FDA granted special permission for the treatment. The first two patients remain alive at six and three months post-treatment. Hemogenyx plans to initiate a second adult dose cohort and a pediatric trial arm, evaluating safety and anti-leukemic activity.

Clarivate has partnered with the University of Melbourne to revolutionize its library systems. Clarivate will provide a comprehensive suite of solutions, including Alma, Primo, Leganto, and Rapido, to create an efficient and user-friendly library platform. This aims to empower library users, optimize operations, and bolster data-driven decision-making, ultimately enhancing teaching, learning, and research. The University of Melbourne aims to align itself with leading institutions globally by implementing this integrated system.